Non-coding RNAs regulating mitochondrial function in cardiovascular diseases

Ao, Xiang; Ding, Wei; Li, Xiaoge; Xu, Qingling; Chen, Xinhui; Zhou, Xuehao; Wang, Jianxun; Liu, Ying

doi:10.1007/s00109-023-02305-8

Cited by 49 publications

(58 citation statements)

References 250 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, they can facilitate target genes' activation or silencing by forming scaffolding complexes with effector molecules. [98,99,100,101] Circular RNA erbb2 interacting protein (circ-ERBIN) regulates the expression of hypoxia-inducible factor (HIF)-1α by binding to miR-125a-5p and miR-138-5p. Circ-ERBIN can accelerate cap-independent protein translation of HIF-1α, and promote colorectal cancer proliferation, migration, and metastasis in vitro and in vivo.…”

Section: Biogenesis and Function Of Circrnasmentioning

confidence: 99%

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Xu,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare and highly aggressive endocrine malignancy. Although surgery can cure localized disease, but the majority of patients experience recurrence of ACC. The 5-year survival rate of patients with metastatic ACC is <15%, and the prognosis is poor. Therefore, it is urgent to explore the potential diagnostic markers and therapeutic targets for ACC. Recently, it has been proved that non-coding RNA (ncRNAs) is widely involved in pathological and physiological processes, including tumorigenesis and development. Aberrantly expressed ncRNAs have been found to be involved in the pathogenesis of ACC. Here, we summarized the expression patterns and the molecular mechanism of the involvement of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in ACC development. To explore the clinical value of ncRNAs as noninvasive biomarkers of ACC, we also displayed the relationship between the expression level of ncRNAs and the diagnosis and prognosis of patients with ACC.

show abstract

Section: Biogenesis and Function Of Circrnasmentioning

confidence: 99%

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Xu,

Zhang

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…■ FUNCTIONAL ROLES OF CIRCNFIXS IN DIFFERENT PHYSIOLOGICAL PROCESSES circNFIX (2) and circNFIX (3,4,5,6,7,8) have been identified to participate in diverse physiological processes, such as myogenesis, heart disease progression, 25,67,70 cancer pathogenesis, 27,47,71 etc. (Figure 3; Table 2).…”

Section: ■ Characteristics Of Circnfixmentioning

confidence: 99%

“…94 Glioma is difficult to cure and easily recur. (3,4,5,6,7,8) was overexpressed in glioma. 27 Bioinformatic analysis, RIP assays and dualluciferase reporter assays showed that circNFIX (3,4,5,6,7,8) could bind to miR-34a-5p and downregulate its expression.…”

Section: ■ Characteristics Of Circnfixmentioning

confidence: 99%

The Role of Circular RNA Variants Generated from the NFIX Gene in Different Diseases

Zhang,

Li,

Gao

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Circular RNAs (circRNAs) have been identified as important regulators in different developmental processes and disease pathogenesis. The loop structure of circRNAs makes them very stable in different conditions and microenvironments. circRNAs can affect microRNA (miRNA) and RNA binding protein (RBP) activity, encode functional proteins and regulate gene transcription. Recently, two circNFIX variants derived from the same gene, the Nuclear Factor I X (NFIX) gene, were determined as participants in the pathological processes of various diseases such as heart diseases and cancers. Both circNFIX variants are exonic circular RNAs and mainly function by sponging miRNAs. In this review, we summarize the current knowledge on circRNAs, elucidate the origins and properties of two circNFIX variants, explore the roles of two circNFIX variants in different diseases, and present clinical perspectives.

show abstract

“…Astonishingly, there has been an almost twofold increase in CVD cases, rising from 271 million in 1990 to 523 million in 2019. Concurrently, cardiovascular‐related fatalities have exhibited a consistent ascent, escalating from 12.1 million to 18.6 million during the same timeframe 168–170 . As a metabolically demanding organ, the heart relies on an adequate energy supply to support its contractile and diastolic functions during both the relaxation and contraction phases.…”

Section: Role Of O‐glcnacylation In Diseasesmentioning

confidence: 99%

O‐GlcNAcylation: cellular physiology and therapeutic target for human diseases

Ye,

Ding,

Xiao

et al. 2023

MedComm

Self Cite

View full text Add to dashboard Cite

O‐linked‐β‐N‐acetylglucosamine (O‐GlcNAcylation) is a distinctive posttranslational protein modification involving the coordinated action of O‐GlcNAc transferase and O‐GlcNAcase, primarily targeting serine or threonine residues in various proteins. This modification impacts protein functionality, influencing stability, protein–protein interactions, and localization. Its interaction with other modifications such as phosphorylation and ubiquitination is becoming increasingly evident. Dysregulation of O‐GlcNAcylation is associated with numerous human diseases, including diabetes, nervous system degeneration, and cancers. This review extensively explores the regulatory mechanisms of O‐GlcNAcylation, its effects on cellular physiology, and its role in the pathogenesis of diseases. It examines the implications of aberrant O‐GlcNAcylation in diabetes and tumorigenesis, highlighting novel insights into its potential role in cardiovascular diseases. The review also discusses the interplay of O‐GlcNAcylation with other protein modifications and its impact on cell growth and metabolism. By synthesizing current research, this review elucidates the multifaceted roles of O‐GlcNAcylation, providing a comprehensive reference for future studies. It underscores the potential of targeting the O‐GlcNAcylation cycle in developing novel therapeutic strategies for various pathologies.

show abstract

Non-coding RNAs regulating mitochondrial function in cardiovascular diseases

Cited by 49 publications

References 250 publications

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

The Role of Circular RNA Variants Generated from the NFIX Gene in Different Diseases

O‐GlcNAcylation: cellular physiology and therapeutic target for human diseases

Contact Info

Product

Resources

About